We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Poolbeg Pharma Plc | POLB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.20 | -1.42% | 13.85 | 10:17:27 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 14.05 | 13.85 | 14.10 | 14.05 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 07/5/2024 22:47 by elrico Sicko, It's unjust to judge others by your own standards. I consistently reveal my sale/top slice a minimum of two trading days in advance if I possess a stated position. Additionally, not everyone can dedicate hundreds of hours each month; some have demanding careers, families, etc. Nevertheless, I do concur that whenever feasible, investors ought to DTOR, such as reviewing independent analyses. You might label these individuals as "cheerleaders" to fit your narrative. Relying on your analyses could have been risky with HVO and POLB, yet one thing is certain, you have been consistently inaccurate.I recall you singing the pump & dump song when POLB share price was c6p. Had anyone been put off by your constant trashing, they would have missed out on healthy gains. I do hope you are pleased with yourself. Instead of just highlighting investors' losses, why not provide some balance by sharing your own? As flawless as you may seem compared to Buffet and Munger, I'm fairly certain you've also had your fair share of failed investments. I know I have over the past 30+ years. Play nice! |
Posted at 06/5/2024 22:20 by davidosh Poolbeg certainly seem to be doing well so do come and meet the management team at Mello 2024Mello2024 investor conference takes place on the 22nd and 23rd May Do come and join us..... We want to keep this important face to face engagement with companies going and it has been tough since Covid as many directors just want to do webinars as their only token offering to investors. If you want to ask private questions or check out body language it is impossible on webinars and investors need to network with each other too. Please support us and encourage companies/ management teams you are in contact with to come along to Mello2024 in Chiswick on 22nd or 23rd May Mello2024 – Mello Events If you have never been to one of our two day conferences before then clearly you are missing a great opportunity to engage with management teams and also network with hundreds of likeminded investors so we are offering virgin tickets at just £30 for either of the days so that you can see what it is all about.....a big discount from £99.00 and if you do not agree having spent the day with us I will give you an annual pass to our virtual shows on top. I just want investors engaging with all these quality smaller companies. This offer is only if you have never attended before so please be fair to all those who pay much more.... Simply enter the code NEW2MELLO24 BUY NOW: |
Posted at 06/5/2024 20:37 by sikhthetech Placing by H1 2025, ie by end of June next year.3 years ago they raised £25m "Oversubscribed fundraise which resulted in an increased raise from £20m to £25m despite some investor scale back" Last week, they said they have £12.2m cash remaining, as of Dec 31st 2023. That balance figure is 4 months old. " Cash balance of £12.2 million as at 31 December 2023" Their admin costs have been increasing and with the new recruits, I think admin costs are now likely to be around £4m pa. Therefore, as of H1 end 2024, end of next month, I think they will have around £10m cash. They have had NIL revenue over the past 3 years. I, therefore, think they will need a placing by end of H1 next year. |
Posted at 30/4/2024 11:07 by chica1 Very few original individual investors made money in Amryt.Aegerion bondholders did! Ever Cathal Friel alluded to this recently. |
Posted at 24/4/2024 14:53 by 1gw This is all very nice but the price action feels both real (i.e. some genuine albeit relatively small scale buying interest) and a bit suspect (i.e. what has changed recently?).If anything I would have thought the apparent delay to results might make investors a bit reluctant at this stage. So does somebody know something? |
Posted at 24/4/2024 14:52 by sikhthetech adorling,What good news? You claiming investors are buying using insider information? Really!! There's lots of small trades to push the share price higher, nothing new, is it? Same PIs churning trades. As of latest AR, fy2022. Revenue NIL, Current mcap £57m |
Posted at 02/2/2024 15:15 by melloteam Just to let shareholders and prospective investors know that Poolbeg Pharma, Time Finance and Duke Royalty will be presenting on the MelloMonday webinar on Monday 19th February 2024, starting at 5pm.There will be over 500 investors attending and these are very popular shows with company presentations, fund manager and investor interviews, and panel sessions. Tickets are still available and if you would like one at half price then enter the code MMTADVFN50. |
Posted at 25/1/2024 23:07 by klosters65 trout You say - MMs took this down to let buyers in at just over 8p, So, you and a load of others, are besotted with the concept that the share price is engineered by Market Makers to help big investors build a large position at a lower price than the rest of us . It has been a good day - long overdue. Let's see in the morning ,how my fellow investors react to this. |
Posted at 05/1/2024 14:57 by 1gw JPM is a major biotech get-together - the main industry event of the year I think. So even if a company is not presenting, there are likely to be planned side-meetings with potential or actual customers, suppliers, partners, investors as well as ad-hoc meetings arranged at the event itself.If POLB is at all serious about a Nasdaq listing or reverse in the next year or two then it needs to be building "share-of-voice" (as I saw it called by another company) with potential US investors and for that having the CFO at the meetings will lend credibility and may actually be essential in some cases (depending on the extent to which the CEO is happy getting into the nitty gritty of the financials). |
Posted at 16/8/2023 23:27 by elrico The Licensing-out is what we investors are waiting for. By way of an apology for my earlier outburst, after seeing my name in a post of klosters trigger the usual suspect, I thought I would try to make amends and bend the knee a little. :)It is worth revisiting the investor deck. I have focused on the licensing-out model because we investors are eager to see news for that. Poolbeg's Licensing-out Lead asset POLB 001 has shown promise as an immunomodulator for severe influenza; the company is well-positioned to license out its technology to larger pharmaceutical corporations. Talks are ongoing! Benefits to Poolbeg (Commercialisation) Licensing allows Poolbeg to generate immediate revenue without the extensive costs and time associated with bringing a drug to market. This revenue often comes in the form of upfront payments, milestone payments based on developmental progress, and royalties from sales. Risk Mitigation By licensing out its technology, Poolbeg can transfer some of the risks associated with drug development, regulatory approvals, and market uncertainties to the licensee. Resource Allocation Licensing enables Poolbeg to allocate its resources more efficiently. Instead of investing heavily in late-stage trials or global market penetration, the company can focus on its core strength: early-stage research and development. Benefits to Licensees (Big Pharma) Access to Innovative Solutions: Licensing allows pharmaceutical giants to access and benefit from Poolbeg's innovative treatments without investing years in research. Faster Time-to-Market With a licensed product, pharmaceutical corporations can reduce the time it takes to introduce a new drug, especially if the product has already undergone initial trials. Diversification For big pharma, licensing is a way to diversify their product portfolio, ensuring they have a mix of products at different stages of development. The Potential of POLB 001 Given the significant unmet need in the influenza market, the licensing potential of POLB 001 is vast. Severe influenza has an economic burden of approximately $11 billion in the US alone. With no suitable drug currently on the market for the 3-5 million severe influenza cases reported globally, the licensing value of POLB 001 could be monumental. Poolbeg's licensing model is a testament to the company's forward-thinking approach. By leveraging its research prowess and offering innovative solutions to larger pharmaceutical entities, Poolbeg ensures a revenue stream and amplifies its impact in the medical world. For investors and industry stakeholders, this model underscores Poolbeg's strategic insight and its potential for sustained growth. A cash balance of £16.2m as of December 2022 is a testament to its sound financial management. It provides a multi-year runway before funds rundown, meaning the BOD are not in a vulnerable negotiation position. Moreover, with a portfolio approach that advances multiple programs in parallel, the risk is effectively spread out, ensuring a higher probability of success. There's plenty of sponsored open-source material at: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
